Published in JAMA Intern Med on August 01, 2014
Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med (2015) 1.77
The health system and population health implications of large-scale diabetes screening in India: a microsimulation model of alternative approaches. PLoS Med (2015) 1.38
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA (2016) 0.96
Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Intern Med (2016) 0.91
In pursuit of normoglycaemia: the overtreatment of type 2 diabetes in general practice. Br J Gen Pract (2015) 0.85
Prevalence of and Racial Disparities in Risk Factor Control in Older Adults With Diabetes: The Atherosclerosis Risk in Communities Study. Diabetes Care (2015) 0.85
Effects of performance measure implementation on clinical manager and provider motivation. J Gen Intern Med (2014) 0.83
Alogliptin benzoate for management of type 2 diabetes. Vasc Health Risk Manag (2015) 0.83
Impact of glucose level on morbidity and mortality in elderly with diabetes and pre-diabetes. World J Diabetes (2015) 0.82
Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study. BMC Endocr Disord (2016) 0.82
Going beyond the disability-based morbidity definition in the compression of morbidity framework. Glob Health Action (2014) 0.81
Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus. J Am Heart Assoc (2016) 0.80
Improving safety of diabetes mellitus management. JAMA Intern Med (2014) 0.77
Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know. J Am Coll Cardiol (2016) 0.77
Older Adults Reporting More Diabetes Mellitus Care Have Greater 9-Year Survival. J Am Geriatr Soc (2015) 0.76
Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status: A retrospective cohort study. Medicine (Baltimore) (2016) 0.76
Emerging utility of once-weekly exenatide in patients with type 2 diabetes. Diabetes Metab Syndr Obes (2015) 0.76
The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes. Diabetes Spectr (2015) 0.75
Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling. Mol Metab (2016) 0.75
Modeling Individual Patient Preferences for Colorectal Cancer Screening Based on Their Tolerance for Complications Risk. Med Decis Making (2016) 0.75
[Is intensive glycemic control for patients with type 2 diabetes profitable? - Diabetes therapy should be more individualised]. Dtsch Med Wochenschr (2014) 0.75
Prevention of complications in type 2 diabetes: is drug glucose control evidence based? Br J Gen Pract (2017) 0.75
Developing, delivering and evaluating primary mental health care: the co-production of a new complex intervention. BMC Health Serv Res (2016) 0.75
Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis. Lancet Diabetes Endocrinol (2016) 0.75
Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. CMAJ (2016) 0.75
"Everyone else gets ice cream here more often than I do-It burns me up" - Perspectives on Diabetes Care from Nursing Home Residents and their Doctors. BMC Geriatr (2016) 0.75
Is glycemia control in Canadians with diabetes individualized? A cross-sectional observational study. BMJ Open Diabetes Res Care (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Cardiovascular disease risk profiles. Am Heart J (1991) 21.65
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet (2009) 10.55
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med (2004) 10.35
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes (1995) 8.89
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA (2000) 7.55
Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia (2009) 6.55
Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc (2003) 6.50
Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA (1997) 6.00
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1991) 5.91
Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA (2002) 4.99
Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA (1988) 4.31
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med (2010) 3.79
Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med (2011) 3.54
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med (2006) 2.73
Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia (2010) 2.71
Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care (1997) 2.63
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med (2010) 2.41
Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med (2005) 2.32
Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care (1997) 2.32
Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA (1990) 2.30
How effective are treatments for diabetic retinopathy? JAMA (1993) 2.25
Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med (1997) 2.22
Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care (2007) 2.17
Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med (2010) 2.06
Patients' perceptions of sharing in decisions: a systematic review of interventions to enhance shared decision making in routine clinical practice. Patient (2012) 1.70
The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care (2010) 1.67
All-or-nothing treatment targets make bad performance measures. Am J Manag Care (2007) 1.61
Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications (2000) 1.46
Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J (2008) 1.44
Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin (2006) 1.44
Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes (1988) 1.40
Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res (2007) 1.39
The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care (2006) 1.38
Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care (2007) 1.20
Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med (1989) 1.13
Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making (1993) 1.09
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ (2010) 1.08
Use of the Health Utilities Index with stroke patients and their caregivers. Stroke (1997) 0.99
Aspirin for primary prevention of cardiovascular events. J Gen Intern Med (1998) 0.94
Humanism in the time of metrics--an essay by David Loxterkamp. BMJ (2013) 0.89
Individualizing glycemic targets in type 2 diabetes mellitus. Ann Intern Med (2011) 0.87
European physicians overestimate life expectancy and the likely impact of interventions in individuals with Type 2 diabetes. Diabet Med (2009) 0.78